Provectus Biopharmaceuticals (Provectus Biopharmaceuticals) Short-Term Debt & Capital Lease Obligation : $3.00 Mil (As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Provectus Biopharmaceuticals Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Provectus Biopharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.00 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Provectus Biopharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.03 Mil.

Provectus Biopharmaceuticals Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Provectus Biopharmaceuticals's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Provectus Biopharmaceuticals Short-Term Debt & Capital Lease Obligation Chart

Provectus Biopharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

0.81

23.71

1.74

2.11

3.00

Provectus Biopharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															2.11	2.58	2.80	3.12	3.00

Provectus Biopharmaceuticals Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Provectus Biopharmaceuticals Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Provectus Biopharmaceuticals's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Provectus Biopharmaceuticals (Provectus Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Provectus Biopharmaceuticals Inc (OTCPK:PVCT) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

800 S Gay St, Suite 1610, Knoxville, TN, USA, 37932

Website

https://www.provectusbio.com

Provectus Biopharmaceuticals Inc is a is a clinical-stage biotechnology company. It is engaged in developing ethical pharmaceuticals for oncology and dermatology indications. The company has developed and intends to license or market and sell its two prescription drug candidates, PV-10 and PH-10. Its PV-10 is for the treatment of several life-threatening cancers including metastatic melanoma, liver cancer, and breast cancer. The PH-10 is to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema.

Executives

Jeffrey Allen Morris	10 percent owner	1729 TRIANGLE PARK DR., MARYVILLE TN 37801
Webster Bailey	director	10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
Heather Raines	officer: Chief Financial Officer	10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
Edward Pershing	director	2220 SOUTHERLAND AVE, KNOXVILLE TN 37919
John Iii Lacy	director	10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
John R Glass	officer: See Remarks	7327 OAK RIDGE HIGHWAY SUITE A, KNOXVILLE TN 37931
Bruce Horowitz	director	7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Dominic Rodrigues	director	7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Peter R Culpepper	officer: Interim CEO, CFO, COO	7327 OAK RIDGE HWY, SUITE A, OAK RIGE TN 37931
Eric Phd Wachter	director, officer: Chief Technology Officer	PROVECTUS PHARMACEUTICALS INC, 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Jan Koe	director	7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Smith Alfred E. Iv	director	191 MAIN STREET, NEW CANAAN CT 06840
Kelly M Mcmasters	director	7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Donald E Adams	10 percent owner	370 CRESTMONT DRIVE, SAN LUIS OBISPO CA 93401
Timothy Phd Scott	director, 10 percent owner, officer: President	PROVECTUS PHARMACEUTICALS INC, 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931